New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
13:07 EDTARIAARIAD presents updated Phase 1/2 data on AP26113
ARIAD Pharmaceuticals announced updated clinical results on its investigational tyrosine kinase inhibitor, TKI, AP26113, in patients with advanced non-small cell lung cancer, NSCLC, from an ongoing Phase 1/2 trial. These study results show anti-tumor activity of AP26113 in patients with crizotinib-resistant anaplastic lymphoma kinase, ALK, positive NSCLC, including patients with brain metastases. Crizotinib is approved for ALK-positive NSCLC patients. The updated Phase 1/2 results are being presented at the 2014 American Society of Clinical Oncology, ASCO, annual meeting in Chicago. “The data from the Phase 2 portion of the trial show that AP26113 exhibits anti-tumor activity in patients with crizotinib-resistant ALK rearranged NSCLC, as well as crizotinib-naïve ALK rearranged NSCLC,” stated Scott N. Gettinger, M.D., associate professor of medicine at Yale School of Medicine. “Importantly, AP26113 demonstrates activity against brain metastases in patients with prior crizotinib therapy, including responses of clinically meaningful duration.”
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
07:38 EDTARIAARIAD issued U.S. patent on brigatinib
Subscribe for More Information
April 21, 2015
14:30 EDTARIAARIAD could be worth double current value to strategic buyer, BBJ BioFlash says
Subscribe for More Information
07:36 EDTARIAARIAD anounces results of preclinical studies on Brigatinib at AACR meeting
ARIAD Pharmaceuticals announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor, brigatinib at the American Association for Cancer Research Annual Meeting 2015. Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer, who are resistant to crizotinib. An oral presentation describes, for the first time, the design and chemical structure of brigatinib, discovered using ARIAD’s structure-based drug design platform. With the goal of designing a selective ALK inhibitor with broad-based activity against crizotinib-resistant mutants, ARIAD scientists advanced a series of novel compounds culminating in the identification of brigatinib. Brigatinib incorporates unique chemical-design features, including the distinctive use of a recognition element that confers favorable pharmacologic properties. Brigatinib has at least 10-fold greater potency than crizotinib against ALK+ NSCLC cell lines and was broadly active against clinically relevant crizotinib-resistant mutants in preclinical models. A poster presentation shows that brigatinib, at clinically achievable concentrations, has potent anti-tumor activity against a panel of 17 distinct ALK mutants known to confer resistance to other ALK inhibitors. In a separate study designed to model the occurrence of brain metastases in ALK+ lung cancer patients, brigatinib significantly reduced the tumor burden in mice with ALK+ brain tumors compared to the tumors in mice treated with crizotinib. Survival of brigatinib-treated mice was also markedly enhanced compared to the survival duration of crizotinib-treated mice.
April 20, 2015
07:20 EDTARIAAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 17, 2015
07:36 EDTARIAARIAD presents updated clinical data on Brigatinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use